These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 28877629)

  • 1. Application of chimeric antigen receptor-engineered T cells in ovarian cancer therapy.
    Zhang M; Zhang DB; Shi H
    Immunotherapy; 2017 Sep; 9(10):851-861. PubMed ID: 28877629
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prospects of chimeric antigen receptor T cell therapy in ovarian cancer.
    Jindal V; Arora E; Gupta S; Lal A; Masab M; Potdar R
    Med Oncol; 2018 Apr; 35(5):70. PubMed ID: 29651744
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adnectin-Based Design of Chimeric Antigen Receptor for T Cell Engineering.
    Han X; Cinay GE; Zhao Y; Guo Y; Zhang X; Wang P
    Mol Ther; 2017 Nov; 25(11):2466-2476. PubMed ID: 28784559
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Current strategies to improve the safety of chimeric antigen receptor (CAR) modified T cells.
    Yang QY; Yang JD; Wang YS
    Immunol Lett; 2017 Oct; 190():201-205. PubMed ID: 28837818
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chimeric antigen receptor T Cells with dissociated signaling domains exhibit focused antitumor activity with reduced potential for toxicity in vivo.
    Lanitis E; Poussin M; Klattenhoff AW; Song D; Sandaltzopoulos R; June CH; Powell DJ
    Cancer Immunol Res; 2013 Jul; 1(1):43-53. PubMed ID: 24409448
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tumor-targeting domains for chimeric antigen receptor T cells.
    Bezverbnaya K; Mathews A; Sidhu J; Helsen CW; Bramson JL
    Immunotherapy; 2017 Jan; 9(1):33-46. PubMed ID: 28000526
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mesothelin as a target for chimeric antigen receptor-modified T cells as anticancer therapy.
    O'Hara M; Stashwick C; Haas AR; Tanyi JL
    Immunotherapy; 2016; 8(4):449-60. PubMed ID: 26973126
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Possible Compartmental Cytokine Release Syndrome in a Patient With Recurrent Ovarian Cancer After Treatment With Mesothelin-targeted CAR-T Cells.
    Tanyi JL; Stashwick C; Plesa G; Morgan MA; Porter D; Maus MV; June CH
    J Immunother; 2017 Apr; 40(3):104-107. PubMed ID: 28234665
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chimeric antigen receptor-redirected T cells return to the bench.
    Geldres C; Savoldo B; Dotti G
    Semin Immunol; 2016 Feb; 28(1):3-9. PubMed ID: 26797495
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prospects to improve chimeric antigen receptor T-cell therapy for solid tumors.
    Jin C; Yu D; Essand M
    Immunotherapy; 2016 Dec; 8(12):1355-1361. PubMed ID: 28000533
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CAR T-cell therapy of solid tumors.
    Yong CSM; Dardalhon V; Devaud C; Taylor N; Darcy PK; Kershaw MH
    Immunol Cell Biol; 2017 Apr; 95(4):356-363. PubMed ID: 28003642
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chimeric antigen receptor engineering: a right step in the evolution of adoptive cellular immunotherapy.
    Figueroa JA; Reidy A; Mirandola L; Trotter K; Suvorava N; Figueroa A; Konala V; Aulakh A; Littlefield L; Grizzi F; Rahman RL; Jenkins MR; Musgrove B; Radhi S; D'Cunha N; D'Cunha LN; Hermonat PL; Cobos E; Chiriva-Internati M
    Int Rev Immunol; 2015 Mar; 34(2):154-87. PubMed ID: 25901860
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Current status and regulatory perspective of chimeric antigen receptor-modified T cell therapeutics.
    Kim MG; Kim D; Suh SK; Park Z; Choi MJ; Oh YK
    Arch Pharm Res; 2016 Apr; 39(4):437-452. PubMed ID: 26895243
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Overcoming barriers of car T-cell therapy in patients with mesothelin-expressing cancers.
    O'Hara MH; Stashwick C; Plesa G; Tanyi JL
    Immunotherapy; 2017 Aug; 9(9):767-780. PubMed ID: 28771103
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of solid tumors with chimeric antigen receptor-engineered T cells: current status and future prospects.
    Di S; Li Z
    Sci China Life Sci; 2016 Apr; 59(4):360-9. PubMed ID: 26968709
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adverse Effects Associated with Clinical Applications of CAR Engineered T Cells.
    Badieyan ZS; Hoseini SS
    Arch Immunol Ther Exp (Warsz); 2018 Aug; 66(4):283-288. PubMed ID: 29427174
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Functional comparison of engineered T cells carrying a native TCR versus TCR-like antibody-based chimeric antigen receptors indicates affinity/avidity thresholds.
    Oren R; Hod-Marco M; Haus-Cohen M; Thomas S; Blat D; Duvshani N; Denkberg G; Elbaz Y; Benchetrit F; Eshhar Z; Stauss H; Reiter Y
    J Immunol; 2014 Dec; 193(11):5733-43. PubMed ID: 25362181
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 'Atypical' CAR T cells: NKG2D and Erb-B as examples of natural receptor/ligands to target recalcitrant solid tumors.
    Gilham DE; Maher J
    Immunotherapy; 2017 Aug; 9(9):723-733. PubMed ID: 28771104
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The promise and potential pitfalls of chimeric antigen receptors.
    Sadelain M; Brentjens R; Rivière I
    Curr Opin Immunol; 2009 Apr; 21(2):215-23. PubMed ID: 19327974
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adoptive immunotherapy for hematological malignancies: Current status and new insights in chimeric antigen receptor T cells.
    Allegra A; Innao V; Gerace D; Vaddinelli D; Musolino C
    Blood Cells Mol Dis; 2016 Nov; 62():49-63. PubMed ID: 27865176
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.